Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

doi:10.1093/annonc/mdx225

Practice Guideline

. 2017 Jul 1;28(suppl_4):iv119-iv142.

doi: 10.1093/annonc/mdx225.

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J B A G Haanen¹, F Carbonnel², C Robert³, K M Kerr⁴, S Peters⁵, J Larkin⁶, K Jordan⁷; ESMO Guidelines Committee

Affiliations

¹ Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands.
² Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
³ Department of Medicine, Dermatology Unit, Gustave Roussy Cancer Campus, Villejuif, France.
⁴ Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Aberdeen, UK.
⁵ Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
⁶ Royal Marsden Hospital NHS Foundation Trust, London, UK.
⁷ Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany.

PMID: 28881921
DOI: 10.1093/annonc/mdx225

Free article

Practice Guideline

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J B A G Haanen et al. Ann Oncol. 2017.

Free article

. 2017 Jul 1;28(suppl_4):iv119-iv142.

doi: 10.1093/annonc/mdx225.

Authors

J B A G Haanen¹, F Carbonnel², C Robert³, K M Kerr⁴, S Peters⁵, J Larkin⁶, K Jordan⁷; ESMO Guidelines Committee

Affiliations

¹ Netherlands Cancer Institute, Division of Medical Oncology, Amsterdam, The Netherlands.
² Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
³ Department of Medicine, Dermatology Unit, Gustave Roussy Cancer Campus, Villejuif, France.
⁴ Department of Pathology, Aberdeen University Medical School & Aberdeen Royal Infirmary, Aberdeen, UK.
⁵ Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
⁶ Royal Marsden Hospital NHS Foundation Trust, London, UK.
⁷ Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Heidelberg, Germany.

PMID: 28881921
DOI: 10.1093/annonc/mdx225

Erratum in

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Haanen JBAG, et al. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266. doi: 10.1093/annonc/mdy162. Ann Oncol. 2018. PMID: 29917046 No abstract available.

No abstract available

PubMed Disclaimer

Cited by

Toxicity-Induced Discontinuation of Immune Checkpoint Inhibitors in Metastatic Urothelial Cancer: 6-Year Experience from a Specialized Uro-Oncology Center.
Rodler S, Aydogdu C, Brinkmann I, Berg E, Kopliku R, Götz M, Ivanova T, Tamalunas A, Schulz GB, Heinemann V, Stief CG, Casuscelli J. Rodler S, et al. Cancers (Basel). 2024 Jun 18;16(12):2246. doi: 10.3390/cancers16122246. Cancers (Basel). 2024. PMID: 38927951 Free PMC article.
Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, Falak R. Kazemi MH, et al. Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022. Front Immunol. 2022. PMID: 36389779 Free PMC article. Review.
An Evaluation of the Use of Corticosteroids for the Management of Immune-Mediated Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Tsui A, Edmondson L, Julius J. Tsui A, et al. J Adv Pract Oncol. 2021 Mar;12(2):137-145. doi: 10.6004/jadpro.2021.12.2.2. Epub 2021 Mar 1. J Adv Pract Oncol. 2021. PMID: 34109046 Free PMC article.
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Dougan M, et al. Support Care Cancer. 2020 Dec;28(12):6129-6143. doi: 10.1007/s00520-020-05707-3. Epub 2020 Aug 27. Support Care Cancer. 2020. PMID: 32856210 Free PMC article. Review.
[Checkpoint inhibitors for cancer therapy].
Zander H, Müller-Egert S, Zwiewka M, Groß S, van Zandbergen G, Engelbergs J. Zander H, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Nov;63(11):1322-1330. doi: 10.1007/s00103-020-03221-9. Epub 2020 Oct 1. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 33001218 Free PMC article. Review. German.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Affiliations

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Authors

Affiliations

Erratum in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Erratum in

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical